Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 15, Number 8—August 2009

Chronic Invasive Aspergillosis caused by Aspergillus viridinutans

Donald C. Vinh1, Yvonne R. Shea1, Pamela A. Jones, Alexandra F. Freeman, Adrian Zelazny, and Steven M. HollandComments to Author 
Author affiliations: National Institutes of Health, Bethesda, Maryland, USA (D.C. Vinh, Y.R. Shea, P.A. Jones, A. Zelazny, S.M. Holland); National Cancer Institute-Frederick, Frederick, Maryland, USA (A.F. Freeman)

Main Article


Antifungal drug susceptibility results of Aspergillus viridinutans isolates relative to A. fumigatus reported at 48 hours*

Isolate Amphotericin B MIC, mg/L Itraconazole MIC, mg/L Voriconazole MIC, mg/L Posaconazole MIC, mg/L Caspofungin MEC, mg/L Terbinafine MIC, mg/L
Patient 1 4 1 1 0.06 0.25 ND
Patient 2† 2–8 8 2–4 <0.016–0.5 0.06–0.25 0.125–1
A. fumigatus B-5233‡ 0.5 0.5 0.5 0.125 0.25 2

*MEC, minimal effective concentration; ND, not determined.
†Composite results of 3 isolates from the patient.
‡Clinical isolate from patient with a fatal case of aspergillosis (courtesy of K.J. Kwon-Chung, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA).

Main Article

1These authors contributed equally to this article.
Page created: November 01, 2010
Page updated: November 01, 2010
Page reviewed: November 01, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.